{"id":6714,"date":"2026-10-13T01:33:06","date_gmt":"2026-10-12T16:33:06","guid":{"rendered":"https:\/\/www.lunit.io\/en\/?post_type=publication&#038;p=6714"},"modified":"2026-10-13T01:33:06","modified_gmt":"2026-10-12T16:33:06","slug":"randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study","status":"publish","type":"publication","link":"https:\/\/www.lunit.io\/en\/publication\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\/","title":{"rendered":"Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study"},"content":{"rendered":"<h2 class=\"title\">Abstract<\/h2>\n<div id=\"eng-abstract\" class=\"abstract-content selected\">\n<p><strong class=\"sub-title\">Background: <\/strong>The benefit of consolidation programmed cell death protein 1 (PD-1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear.<\/p>\n<p><strong class=\"sub-title\">Methods: <\/strong>Patients with stages II-IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy. The primary endpoint was 3-year progression-free survival (PFS).<\/p>\n<p><strong class=\"sub-title\">Results: <\/strong>Fifty-three patients were randomized (pembrolizumab, n = 34; placebo, n = 19). The 3-year PFS rates were 56.5% and 57.8% in the pembrolizumab and placebo arms, respectively (one-sided p = 0.142; stratified HR, 0.408). Grade 3 or higher adverse events occurred only in the pembrolizumab arm (8.8%). In an exploratory analysis (n = 40), high intratumoral TIL density was associated with reduced recurrence in the pembrolizumab arm (OR, 0.04; p = 0.010) but not the placebo arm.<\/p>\n<p><strong class=\"sub-title\">Conclusions: <\/strong>Consolidation pembrolizumab did not improve PFS in unselected locally advanced NPC. Exploratory immune profiling suggested a predictive signal warranting prospective validation.<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42168759\/\">See Abstract<\/a><\/p>\n<\/div>\n","protected":false},"featured_media":0,"template":"","publication-oncology":[83,133,94],"publication-region":[87],"publication-type":[],"radiology":[],"class_list":["post-6714","publication","type-publication","status-publish","hentry","publication-oncology-head-and-neck","publication-oncology-lunit-scope-io","publication-oncology-peer-reviewed-clinical-papers","publication-region-asia"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study - Lunit<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lunit.io\/en\/publication\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study - Lunit\" \/>\n<meta property=\"og:description\" content=\"Abstract Background: The benefit of consolidation programmed cell death protein 1 (PD-1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods: Patients with stages II-IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy. The primary endpoint was 3-year progression-free survival [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lunit.io\/en\/publication\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Lunit\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@lunit_ai\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/publication\\\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\\\/\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/publication\\\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\\\/\",\"name\":\"Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study - Lunit\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/#website\"},\"datePublished\":\"2026-10-12T16:33:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/publication\\\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.lunit.io\\\/en\\\/publication\\\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/publication\\\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/\",\"name\":\"Lunit\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/#organization\",\"name\":\"Lunit\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Logo-black.svg\",\"contentUrl\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Logo-black.svg\",\"width\":189,\"height\":52,\"caption\":\"Lunit\"},\"image\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/lunit_ai\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/lunit-inc\",\"https:\\\/\\\/x.com\\\/lunitoncology\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study - Lunit","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lunit.io\/en\/publication\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\/","og_locale":"en_US","og_type":"article","og_title":"Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study - Lunit","og_description":"Abstract Background: The benefit of consolidation programmed cell death protein 1 (PD-1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods: Patients with stages II-IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy. The primary endpoint was 3-year progression-free survival [&hellip;]","og_url":"https:\/\/www.lunit.io\/en\/publication\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\/","og_site_name":"Lunit","twitter_card":"summary_large_image","twitter_site":"@lunit_ai","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lunit.io\/en\/publication\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\/","url":"https:\/\/www.lunit.io\/en\/publication\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\/","name":"Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study - Lunit","isPartOf":{"@id":"https:\/\/www.lunit.io\/en\/#website"},"datePublished":"2026-10-12T16:33:06+00:00","breadcrumb":{"@id":"https:\/\/www.lunit.io\/en\/publication\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lunit.io\/en\/publication\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.lunit.io\/en\/publication\/randomized-phase-ii-trial-of-consolidation-pembrolizumab-after-definitive-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-kcsg-hn19-09-conpelan-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lunit.io\/en\/"},{"@type":"ListItem","position":2,"name":"Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study"}]},{"@type":"WebSite","@id":"https:\/\/www.lunit.io\/en\/#website","url":"https:\/\/www.lunit.io\/en\/","name":"Lunit","description":"","publisher":{"@id":"https:\/\/www.lunit.io\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lunit.io\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.lunit.io\/en\/#organization","name":"Lunit","url":"https:\/\/www.lunit.io\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.lunit.io\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.lunit.io\/en\/wp-content\/uploads\/2025\/10\/Logo-black.svg","contentUrl":"https:\/\/www.lunit.io\/en\/wp-content\/uploads\/2025\/10\/Logo-black.svg","width":189,"height":52,"caption":"Lunit"},"image":{"@id":"https:\/\/www.lunit.io\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/lunit_ai","https:\/\/www.linkedin.com\/company\/lunit-inc","https:\/\/x.com\/lunitoncology"]}]}},"_links":{"self":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/publication\/6714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/media?parent=6714"}],"wp:term":[{"taxonomy":"publication-oncology","embeddable":true,"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/publication-oncology?post=6714"},{"taxonomy":"publication-region","embeddable":true,"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/publication-region?post=6714"},{"taxonomy":"publication-type","embeddable":true,"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/publication-type?post=6714"},{"taxonomy":"radiology","embeddable":true,"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/radiology?post=6714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}